IS6727A - Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlar - Google Patents

Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlar

Info

Publication number
IS6727A
IS6727A IS6727A IS6727A IS6727A IS 6727 A IS6727 A IS 6727A IS 6727 A IS6727 A IS 6727A IS 6727 A IS6727 A IS 6727A IS 6727 A IS6727 A IS 6727A
Authority
IS
Iceland
Prior art keywords
glucogenophosphorylase
pyrrolylamide
inhibitors
ring
amide derivatives
Prior art date
Application number
IS6727A
Other languages
English (en)
Other versions
IS2110B (is
Inventor
B. Bartlett Julie
Freeman Sue
Kenny Peter
Morley Andrew
Whittamore Paul
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6727A publication Critical patent/IS6727A/is
Publication of IS2110B publication Critical patent/IS2110B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IS6727A 2000-09-06 2003-02-24 Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlar IS2110B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021831.3A GB0021831D0 (en) 2000-09-06 2000-09-06 Chemical compounds
PCT/SE2001/001880 WO2002020530A1 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors

Publications (2)

Publication Number Publication Date
IS6727A true IS6727A (is) 2003-02-24
IS2110B IS2110B (is) 2006-05-15

Family

ID=9898927

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6727A IS2110B (is) 2000-09-06 2003-02-24 Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlar

Country Status (30)

Country Link
US (1) US20030232875A1 (is)
EP (1) EP1317459B1 (is)
JP (1) JP2004508376A (is)
KR (1) KR100802369B1 (is)
CN (2) CN1264846C (is)
AT (1) ATE263772T1 (is)
AU (2) AU2001282833B2 (is)
BG (1) BG107624A (is)
BR (1) BR0113606A (is)
CA (1) CA2417594A1 (is)
CZ (1) CZ2003616A3 (is)
DE (1) DE60102710T2 (is)
DK (1) DK1317459T3 (is)
EE (1) EE200300083A (is)
ES (1) ES2217183T3 (is)
GB (1) GB0021831D0 (is)
HU (1) HUP0400784A3 (is)
IL (1) IL154291A0 (is)
IS (1) IS2110B (is)
MX (1) MXPA03001512A (is)
NO (1) NO20031024D0 (is)
NZ (1) NZ524011A (is)
PL (1) PL361024A1 (is)
PT (1) PT1317459E (is)
RU (1) RU2003104013A (is)
SK (1) SK2592003A3 (is)
TR (1) TR200401659T4 (is)
UA (1) UA73781C2 (is)
WO (1) WO2002020530A1 (is)
ZA (1) ZA200301013B (is)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) * 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
ATE444284T1 (de) * 2002-06-17 2009-10-15 Saltigo Gmbh Verfahren zur herstellung von mono-n- sulfonylierten diaminen
EP1523471B1 (de) * 2002-07-11 2009-09-16 Sanofi-Aventis Deutschland GmbH Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
GB0222912D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
MXPA05004968A (es) * 2002-11-07 2005-08-02 Pfizer Prod Inc N-(indol-z-carbonil)amidas como agentes anti-diabeticos.
MXPA05011176A (es) * 2003-04-17 2005-12-14 Pfizer Prod Inc Derivados de carboxamida como agentes antidiabeticos.
MXPA05012547A (es) * 2003-05-21 2006-05-25 Prosidion Ltd Inhibidores de amida de acido pirrolopiridina-2-carboxilico de fosforilasa de glucogeno.
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2004113345A1 (ja) * 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
GB0318463D0 (en) * 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0318464D0 (en) * 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319690D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2005020986A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
WO2005020985A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
GB0320422D0 (en) * 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds
RU2361862C2 (ru) 2003-12-29 2009-07-20 Сепракор Инк. Пиррольные и пиразольные ингибиторы daao
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
WO2006053274A2 (en) * 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
JP2008521874A (ja) * 2004-12-02 2008-06-26 プロシディオン・リミテッド グリコーゲンホスホリラーゼのインヒビターとして有用なピロロピリジン−２−カルボン酸アミド誘導体
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
DE602006021535D1 (de) * 2005-01-19 2011-06-09 Merck Sharp & Dohme Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
JP2008528666A (ja) * 2005-02-05 2008-07-31 アストラゼネカ アクチボラグ グリコーゲンホスホリラーゼ阻害活性を有するインダンアミド誘導体
EP1848721A1 (en) * 2005-02-05 2007-10-31 AstraZeneca AB Chemical compounds
US8053603B2 (en) 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
BRPI0706365A2 (pt) 2006-01-06 2011-03-22 Sepracor Inc Cicloalquilaminas como inibidores da recaptação de monoamina
EP2816024B8 (en) 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
JP5306818B2 (ja) * 2006-10-18 2013-10-02 武田薬品工業株式会社 縮合複素環化合物
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CA2688493C (en) 2007-05-31 2016-04-19 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100152200A1 (en) * 2008-11-17 2010-06-17 The Regents Of The University Of Michigan Alphavirus inhibitors and uses thereof
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
CN111978319B (zh) 2014-06-27 2023-08-11 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
CA3094197C (en) 2015-07-02 2023-02-28 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
IL287136B2 (en) * 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CN112074519B (zh) 2018-04-20 2024-08-02 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物
CN118496217A (zh) 2018-11-20 2024-08-16 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
TW202115086A (zh) * 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
EP4066896A4 (en) * 2019-11-27 2024-03-27 Riken G9A INHIBITOR

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
ES2081747B1 (es) * 1993-09-07 1997-01-16 Esteve Labor Dr Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2723739B1 (fr) * 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP1062218A1 (en) * 1998-03-12 2000-12-27 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
PT1088824E (pt) * 1999-09-30 2004-04-30 Pfizer Prod Inc Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use

Also Published As

Publication number Publication date
CZ2003616A3 (cs) 2003-05-14
BG107624A (bg) 2004-01-30
EP1317459A1 (en) 2003-06-11
GB0021831D0 (en) 2000-10-18
WO2002020530A1 (en) 2002-03-14
CA2417594A1 (en) 2002-03-14
IL154291A0 (en) 2003-09-17
JP2004508376A (ja) 2004-03-18
HUP0400784A2 (hu) 2004-07-28
IS2110B (is) 2006-05-15
RU2003104013A (ru) 2004-08-20
HK1055299A1 (en) 2004-01-02
CN1264846C (zh) 2006-07-19
ES2217183T3 (es) 2004-11-01
US20030232875A1 (en) 2003-12-18
EP1317459B1 (en) 2004-04-07
NZ524011A (en) 2004-08-27
NO20031024L (no) 2003-03-05
HUP0400784A3 (en) 2007-09-28
KR100802369B1 (ko) 2008-02-14
NO20031024D0 (no) 2003-03-05
DE60102710T2 (de) 2005-04-14
PT1317459E (pt) 2004-08-31
BR0113606A (pt) 2003-06-24
SK2592003A3 (en) 2003-08-05
AU2001282833B2 (en) 2006-07-06
DE60102710D1 (de) 2004-05-13
EE200300083A (et) 2004-12-15
TR200401659T4 (tr) 2004-09-21
PL361024A1 (en) 2004-09-20
AU8283301A (en) 2002-03-22
DK1317459T3 (da) 2004-07-12
ZA200301013B (en) 2004-05-05
UA73781C2 (en) 2005-09-15
CN1473163A (zh) 2004-02-04
CN1896078A (zh) 2007-01-17
KR20030025305A (ko) 2003-03-28
MXPA03001512A (es) 2003-06-09
ATE263772T1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
IS2110B (is) Bíhringtengd pýrrólýlamíð sem glúkógenfosfórýlasahemlar
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
YU20999A (sh) Heterociklični derivati koji inhibiraju faktor xa
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
CA2338220A1 (en) Substituted imidazoles having cytokine inhibitory activity
WO2001066564A3 (en) Gamma-secretase inhibitors
JO2282B1 (en) Oxazole derivatives
GB0225475D0 (en) Therapeutic agents
CA2336909A1 (en) Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
BR0214277A (pt) Solvatos de paclitaxel
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
CA2260777A1 (en) Pentafluorobenzenesulfonamides and analogs
DE60045508D1 (de) Dalda-analoge und ihre verwendung
EP1126836A4 (en) BENZAMIDES AS POTASSIUM CHANNEL INHIBITORS
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
NO20052182L (no) Nye forbindelser
GB9601722D0 (en) Heterocyclic derivatives
AP2000001761A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
PT1056754E (pt) Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
AP2000001760A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
WO2004037166A3 (en) Therapeutic guanidines
WO2001005386A3 (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss